MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …

Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

Abstract Aim The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management
of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the …

The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Background: Ibrutinib is a Bruton tyrosine kinase inhibitor with remarkable efficacy against B-
cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly …

Background: Ibrutinib has revolutionized treatment for several B-cell malignancies.
However, a recent clinical trial where ibrutinib was used in a front-line setting showed …

Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging
evidence suggests common mechanisms between cancer and cardiovascular disease …

In the cardio-oncology population, drug interactions are of particular importance given the
complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies …

With the advent of novel cancer therapeutics and improved screening, more patients are
surviving a cancer diagnosis or living longer with advanced disease. Many of these …

Cancer diagnostics and therapies have improved steadily over the last few decades,
markedly increasing life expectancy for patients at all ages. However, conventional and …